Quantum-Si Incorporated (NASDAQ: QSI) has announced the pricing of a registered direct offering of 15,625,000 shares of common stock at a purchase price of $3.20 per share, resulting in gross proceeds of approximately $50 million. The offering is expected to close on or about January 6, 2025, subject to customary closing conditions.
The net proceeds from the offering will be used for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
This offering is being made pursuant to an effective shelf registration statement on Form S-3, which was declared effective by the Securities and Exchange Commission (SEC) on August 22, 2023.
Quantum-Si, the protein sequencing company™, is focused on revolutionizing the field of proteomics with its Platinum® instrument, which enables next-gen protein sequencing™. The company aims to advance proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools.
It's important to note that the company's recent offering of common stock aligns with its commitment to furthering its mission in the field of proteomics. As a result of these announcements, the company's shares have moved -4.5% on the market, and are now trading at a price of $4.09. For more information, read the company's full 8-K submission here.
